Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 8;17(7):1087.
doi: 10.3390/ijms17071087.

Chemical Structure-Biological Activity Models for Pharmacophores' 3D-Interactions

Affiliations
Review

Chemical Structure-Biological Activity Models for Pharmacophores' 3D-Interactions

Mihai V Putz et al. Int J Mol Sci. .

Abstract

Within medicinal chemistry nowadays, the so-called pharmaco-dynamics seeks for qualitative (for understanding) and quantitative (for predicting) mechanisms/models by which given chemical structure or series of congeners actively act on biological sites either by focused interaction/therapy or by diffuse/hazardous influence. To this aim, the present review exposes three of the fertile directions in approaching the biological activity by chemical structural causes: the special computing trace of the algebraic structure-activity relationship (SPECTRAL-SAR) offering the full analytical counterpart for multi-variate computational regression, the minimal topological difference (MTD) as the revived precursor for comparative molecular field analyses (CoMFA) and comparative molecular similarity indices analysis (CoMSIA); all of these methods and algorithms were presented, discussed and exemplified on relevant chemical medicinal systems as proton pump inhibitors belonging to the 4-indolyl,2-guanidinothiazole class of derivatives blocking the acid secretion from parietal cells in the stomach, the 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine congeners' (HEPT ligands) antiviral activity against Human Immunodeficiency Virus of first type (HIV-1) and new pharmacophores in treating severe genetic disorders (like depression and psychosis), respectively, all involving 3D pharmacophore interactions.

Keywords: chemical stericity; cross-validation; drug design; hydrophobicity; ligand binding; molecular mechanism; multi-linear correlation; quantitative structure-activity relationship (QSAR); statistical correlation; van der Waals interaction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The electronic basins (left) and the associated electrostatic potential contours (right) for 4-(5-methylindolyl)-2-methylheptylguanidinothiazole, displaying optimized maximum electrophilic activity by the predicted special computing trace of the algebraic structure-activity relationship (SPECTRAL-SAR) mechanism action [56]. Green lines correspond with highest occupied molecular orbitals (HOMO), magenta with lowest unoccupied molecular orbitals (LUMO) with the yellow shapes marked as key fragments for chemical frontier reactivity.
Figure 2
Figure 2
1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine (HEPT) structure with superimposition of 79 derivatives with minimum energy conformations; these are (marked in blue, in the center) the possible positions for substituents of the uracil ring; also in blue, we marked the 63 obtained vertices [19]; down arrows and triangles denote those beneficial vertices (attributed to the receptor cavity), up arrows and triangles indicate the detrimental vertices, for the mono-linear and bi-linear MTD analysis of Equations (17) and (19) and the optimized charts (18) and (20), respectively; see the text for further details. Circular colors generally indicate self-corresponding visualization for the molecular group belonging in the hypermolecule.

References

    1. Pandey A.V. Bioinformatics tools and databases for the study of human growth hormone. Endocr. Dev. 2012;23:71–85. - PubMed
    1. Koedrith P., Kim H., Weon J., Seo Y.R. Toxicogenomic approaches for understanding molecular mechanisms of heavy metal mutagenicity and carcinogenicity. Int. J. Hyg. Environ. Health. 2013;216:587–598. doi: 10.1016/j.ijheh.2013.02.010. - DOI - PubMed
    1. Tang M., Odejinmi S.I., Vankayalapati H., Wierenga K.J., Lai K. Innovative therapy for Classic Galactosemia—Tale of two HTS. Mol. Genet. Metab. 2012;105:44–55. doi: 10.1016/j.ymgme.2011.09.028. - DOI - PMC - PubMed
    1. Hurko O. Target-based drug discovery, genetic diseases, and biologics. Neurochem. Int. 2012;61:892–898. doi: 10.1016/j.neuint.2012.01.016. - DOI - PubMed
    1. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 2000;28:235–242. doi: 10.1093/nar/28.1.235. - DOI - PMC - PubMed

LinkOut - more resources